drugset / Trial / NCT02506751

Open-label Study of Liothyronine in MS

NCT02506751

Phase 1 Completed 20 enrolled Johns Hopkins University
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.

Timeline

Start
2015-07
Primary completion
2017-09-18
Completion
2017-09-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Liothyronine Small molecule 1 ug/kg Oral